성매개감염 진단의 현재와 향후 발전 방향

키워드

참고문헌 (53)

1. "Sexually Transmitted Infections (STIs)"[URL]
2. Global Health Sector Strategy On Sexually Transmitted Infections, 2016-2021, "WHO", World Health Organization, ~ (2016)
3. Kraus SJ, "Culture methods for Neisseria gonorrhoea", Arch Androl, 3, pp.343~349 (1979)
4. Peng L, "Progress and perspectives in point of care testing for urogenital Chlamydia trachomatis infection : a review", Med Sci Monit, 26, pp.e920873~ (2020)
5. Meyer T, "The laboratory diagnosis of Neisseria gonorrhoeae : current testing and future demands", Pathogens, 9, pp.91~ (2020)
6. Gaydos CA, "Rapid and point-of-care tests for the diagnosis of Trichomonas vaginalis in women and men", Sex Transm Infect, 93, pp.S31~S35 (2017)
7. Herring A, "Evaluation of rapid diagnostic tests : chlamydia and gonorrhoea", Nat Rev Microbiol, 4, pp.S41~S48 (2006)
8. Seña AC, "Novel Treponema pallidum serologic tests : a paradigm shift in syphilis screening for the 21st century", Clin Infect Dis, 51, pp.700~708 (2010)
9. Nsuami M, "Recommendations for screening high school students for chlamydia and gonorrhea in San Francisco", Sex Transm Dis, 30, pp.367~ (2003)
10. Ford CA, "Testing for chlamydial and gonorrheal infections outside of clinic settings : a summary of the literature", Sex Transm Dis, 31, pp.38~51 (2004)
11. Dumkow LE, "Syndromic diagnostic testing : a new way to approach patient care in the treatment of infectious diseases", J Antimicrob Chemother, 76, pp.iii4~iii11 (2021)
12. Ramanan P, "Syndromic panel-based testing in clinical microbiology", Clin Microbiol Rev, 31, pp.e00024-17~ (2018)
13. Popowitch EB, "Comparison of the Biofire FilmArray RP, Genmark eSensor RVP, Luminex xTAG RVPv1, and Luminex xTAG RVP fast multiplex assays for detection of respiratory viruses", J Clin Microbiol, 51, pp.1528~1533 (2013)
14. Ward C, "Performance evaluation of the Verigene®(Nanosphere)and FilmArray®(BioFire®)molecular assays for identification of causative organisms in bacterial bloodstream infections", Eur J Clin Microbiol Infect Dis, 34, pp.487~496 (2015)
15. WHO, "Guidelines for the management of symptomatic sexually transmitted infections", World Health Organization, ~ (2021)
16. Nelson K, "P058 Design and performance of the alinity m STI assay for the detection of CT, NG, TV, and MG", Sex Transm Infect, 95, pp.A103~ (2019)
17. Hristov A, "P268 Clinical performance assessment of the Alinity m STI assay", Sex Transm Infect, 97, pp.A129~A130 (2021)
18. Huh HJ, "Comparison between DiaPlexQ™STI6 and GeneFinder™ STD I", STD II multiplex Real-time PCR Kits in the detection of six sexually transmitted disease pathogens, 2019, pp.33, e22703~
19. Park HJ, "Trend analysis of the profiles of 12 sexually transmitted disease pathogens in the Republic of Korea in 2019", Inquiry, 58 (2021)
20. CDC, "Sexually transmitted diseases treatment guidelines", Ann Emerg Med, 58, pp.67~68 (2011)
21. Xie TA, "Evaluation of the diagnostic efficacy of Xpert CT", NG for Chlamydia trachomatis and Neisseria gonorrhoeae, 2020, pp.2020, 2892734~
22. Dukers-Muijrers NH, "What is needed to guide testing for anorectal and pharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae in women and men? Evidence and opinion", BMC Infect Dis, 15, pp.533~ (2015)
23. Cristillo AD, "Point-ofcare sexually transmitted infection diagnostics: proceedings of the STAR sexually transmitted infection-clinical trial group programmatic meeting", Sex Transm Dis, 44, pp.211~218 (2017)
24. Herbst de Cortina S, "A systematic review of point of care testing for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis", Infect Dis Obstet Gynecol, 2016, pp.4386127~ (2016)
25. Tucker JD, "Point-of-care testing for sexually transmitted infections : recent advances and implications for disease control", Curr Opin Infect Dis, 26, pp.73~79 (2013)
26. Barrow RY, "Recommendations for providing quality sexually transmitted diseases clinical services, 2020", MMWR Recomm Rep, 68, pp.1~20 (2020)
27. Peeling RW, "Rapid tests for sexually transmitted infections(STIs) : the way forward", Sex Transm Infect, 82(Suppl 5), pp.v1~v6 (2006)
28. Hsieh YH, "What qualities are most important to making a point of care test desirable for clinicians and others offering sexually transmitted infection testing?", PLoS One, 6, pp.e19263~ (2011)
29. Cosentino LA, "Use of nucleic acid amplification testing for diagnosis of extragenital sexually transmitted infections", J Clin Microbiol, 55, pp.2801~2807 (2017)
30. Gettinger J, "Patients are willing to wait for rapid sexually transmitted infection results in a university student health clinic", Sex Transm Dis, 47, pp.67~69 (2020)
31. Van Der Pol B, "A profile of the binx health io® molecular point-of-care test for chlamydia and gonorrhea in women and men", Expert Rev Mol Diagn, 21, pp.861~868 (2021)
32. Van Der Pol B, "Evaluation of the performance of a point-of-care test for chlamydia and gonorrhea", JAMA Netw Open, 3, pp.e204819~ (2020)
33. Antibiotic Resistance Threats in the United States, 2019, "CDC", U.S. Department of Health and Human Services, ~ (2019)
34. Lewis DA, "Global resistance of Neisseria gonorrhoeae : when theory becomes reality", Curr Opin Infect Dis, 27, pp.62~67 (2014)
35. Wi T, "Antimicrobial resistance in Neisseria gonorrhoeae : global surveillance and a call for international collaborative action", PLoS Med, 14, pp.e1002344~ (2017)
36. CDC, "Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections", MMWR Morb Mortal Wkly Rep, 56, pp.332~336 (2007)
37. Lee H, "Emergence and spread of cephalosporin-resistant Neisseria gonorrhoeae with mosaic penA alleles, South Korea, 2012-2017", Emerg Infect Dis, 25, pp.416~424 (2019)
38. Gernert KM, "Azithromycin susceptibility of Neisseria gonorrhoeae in the USA in 2017 : a genomic analysis of surveillance data", Lancet Microbe, 1, pp.e154~e164 (2020)
39. Clegg A, "High rates of genital mycoplasma infection in the highlands of Papua New Guinea determined both by culture and by a commercial detection kit", J Clin Microbiol, 35, pp.197~200 (1997)
40. Waites KB, "Mycoplasmas and ureaplasmas as neonatal pathogens", Clin Microbiol Rev, 18, pp.757~789 (2005)
41. Murtha AP, "The role of Mycoplasma and Ureaplasma in adverse pregnancy outcomes", Obstet Gynecol Clin, 41, pp.615~627 (2014)
42. Song T, "Epidemiological investigation and antimicrobial susceptibility analysis of ureaplasma species and Mycoplasma hominis in outpatients with genital manifestations", J Clin Pathol, 67, pp.817~820 (2014)
43. Valentine-King MA, "Antibacterial resistance in Ureaplasma species and Mycoplasma hominis isolates from urine cultures in college-aged females", Antimicrob Agents Chemother, 61, pp.e01104-17~ (2017)
44. Lis R, "Mycoplasma genitalium infection and female reproductive tract disease : a meta-analysis", Clin Infect Dis, 61, pp.418~426 (2015)
45. Taylor-Robinson D, "Mycoplasma genitalium : from chrysalis to multicolored butterfly", Clin Microbiol Rev, 24, pp.498~514 (2011)
46. Jensen JS, "2016 European guideline on Mycoplasma genitalium infections", J Eur Acad Dermatol Venereol, 30, pp.1650~1656 (2016)
47. "Korean Guideline for Sexually Transmitted Infection", Korean Centers for Disease Control and Prevention, ~ (2016)
48. Jensen JS, "Diagnosis of Sexually Transmitted Diseases", pp.129~139 (2012), Humana Press
49. Tagg KA, "Fluoroquinolone and macrolide resistance-associated mutations in Mycoplasma genitalium", J Clin Microbiol, 51, pp.2245~2249 (2013)
50. Hadad R, "Evaluation of the SpeeDx ResistancePlus® GC and SpeeDx GC 23S 2611(beta)molecular assays for prediction of antimicrobial resistance", susceptibility to ciprofloxacin and azithromycin in Neisseria gonorrhoeae, 2021, pp.76, 84~90
51. Gardette M, "Clinical performance of three commercial molecular diagnostic assays for the detection of fluoroquinolone resistanceassociated mutations in Mycoplasma genitalium", J Clin Microbiol, 60, pp.e01135-22~ (2022)
52. Sweeney EL, "Evaluation of the SpeeDx MG parC(Beta)PCR assay for rapid detection of Mycoplasma genitalium quinolone resistanceassociated mutations", J Clin Microbiol, 58, pp.e01432-20~ (2020)
53. "Performance of the first commercial dual resistance assay, AmpliSens Mycoplasma genitalium-ML/FQ-Resist-FL, for detection of potential macrolide and quinolone resistanceassociated mutations and prevalence of M. genitalium resistance mutations in St. Petersburg, Russia" (2022)[URL]

관련 논문AI추천